Browsing Tag
primary sclerosing cholangitis
2 posts
How the cholestatic liver disease market is creating new opportunities for NTCP-targeting therapies
Assembly Biosciences is expanding ABI-6250 into PBC and PSC. Find out why NTCP-targeting therapies are gaining momentum in hepatology.
Mirum Pharmaceuticals (NASDAQ: MIRM) jumps 13% after VISTAS Phase 2b PSC win
Two Phase 2b wins in seven days. A pre-NDA meeting this summer. Mirum is starting to look less like a single-product rare disease story.